{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T01:09:00Z","timestamp":1789002540975,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T00:00:00Z","timestamp":1638144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2018ZX09201016"],"award-info":[{"award-number":["2018ZX09201016"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2018ZX10302204-004"],"award-info":[{"award-number":["2018ZX10302204-004"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"crossref","award":["2017ZX10203202-003"],"award-info":[{"award-number":["2017ZX10203202-003"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Project of Beijing Municipal Science and Technology Commission","award":["D161100002716003"],"award-info":[{"award-number":["D161100002716003"]}]},{"name":"Project of the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority","award":["XXZ0405"],"award-info":[{"award-number":["XXZ0405"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s12072-021-10240-4","type":"journal-article","created":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T06:02:41Z","timestamp":1638165761000},"page":"1318-1327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis"],"prefix":"10.1007","volume":"15","author":[{"given":"Xiaoning","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yameng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilin","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongtong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingqiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4673-8890","authenticated-orcid":false,"given":"Jidong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,29]]},"reference":[{"key":"10240_CR1","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","volume":"386","author":"A Schweitzer","year":"2015","unstructured":"Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386:1546\u20131555","journal-title":"Lancet"},{"key":"10240_CR2","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","volume":"68","author":"GV Papatheodoridis","year":"2018","unstructured":"Papatheodoridis GV, Sypsa V, Dalekos G, Yurdaydin C, van Boemmel F, Buti M, et al. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. J Hepatol. 2018;68:1129\u20131136","journal-title":"J Hepatol"},{"key":"10240_CR3","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/S0140-6736(18)31865-8","volume":"392","author":"WK Seto","year":"2018","unstructured":"Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet. 2018;392:2313\u20132324","journal-title":"Lancet"},{"key":"10240_CR4","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1002\/hep.31550","volume":"73","author":"M Verma","year":"2021","unstructured":"Verma M, Younossi Z. Integrating patient reported outcomes within routine hepatology care: a prompt to action. Hepatology. 2021;73:1570\u20131580","journal-title":"Hepatology"},{"key":"10240_CR5","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/hep.22138","volume":"47","author":"SC Ong","year":"2008","unstructured":"Ong SC, Mak B, Aung MO, Li SC, Lim SG. Health-related quality of life in chronic hepatitis B patients. Hepatology. 2008;47:1108\u20131117","journal-title":"Hepatology"},{"key":"10240_CR6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.jhep.2014.06.034","volume":"61","author":"JG Orr","year":"2014","unstructured":"Orr JG, Homer T, Ternent L, Newton J, McNeil CJ, Hudson M, et al. Health related quality of life in people with advanced chronic liver disease. J Hepatol. 2014;61:1158\u20131165","journal-title":"J Hepatol"},{"key":"10240_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/1477-7525-12-101","volume":"12","author":"G Zhuang","year":"2014","unstructured":"Zhuang G, Zhang M, Liu Y, Guo Y, Wu Q, Zhou K, et al. Significant impairment of health-related quality of life in mainland Chinese patients with chronic hepatitis B: a cross-sectional survey with pair-matched healthy controls. Health Qual Life Outcomes. 2014;12:101","journal-title":"Health Qual Life Outcomes"},{"key":"10240_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1477-7525-7-52","volume":"7","author":"ET Lam","year":"2009","unstructured":"Lam ET, Lam CL, Lai CL, Yuen MF, Fong DY, So TM. Health-related quality of life of Southern Chinese with chronic hepatitis B infection. Health Qual Life Outcomes. 2009;7:52","journal-title":"Health Qual Life Outcomes"},{"key":"10240_CR9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejim.2019.09.004","volume":"70","author":"C Labenz","year":"2019","unstructured":"Labenz C, Toenges G, Schattenberg JM, Nagel M, Huber Y, Marquardt JU, et al. Health-related quality of life in patients with compensated and decompensated liver cirrhosis. Eur J Intern Med. 2019;70:54\u201359","journal-title":"Eur J Intern Med"},{"key":"10240_CR10","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.cgh.2019.07.047","volume":"18","author":"ZM Younossi","year":"2020","unstructured":"Younossi ZM, Stepanova M, Racila A, Afendy A, Lawitz EJ, Schwabe C, et al. Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2020;18:468\u2013476","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 3","key":"10240_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/jvh.13005","volume":"25","author":"Z Younossi","year":"2018","unstructured":"Younossi Z, Papatheodoridis G, Cacoub P, Negro F, Wedemeyer H, Henry L, et al. The comprehensive outcomes of hepatitis C virus infection: a multi-faceted chronic disease. J Viral Hepatol. 2018;25(Suppl 3):6\u201314","journal-title":"J Viral Hepatol"},{"key":"10240_CR12","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/hep.20659","volume":"4","author":"BM Spiegel","year":"2005","unstructured":"Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;4:790\u2013800","journal-title":"Hepatology"},{"key":"10240_CR13","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cgh.2018.09.041","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Younossi I, Pan CQ, Janssen HLA, Papatheodoridis G, et al. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. Clin Gastroenterol Hepatol. 2019;17:1641\u20131642","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10240_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12955-016-0557-9","volume":"14","author":"Z Karacaer","year":"2016","unstructured":"Karacaer Z, Cakir B, Erdem H, Ugurlu K, Durmus G, Ince NK, et al. Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study. Turkey Health Qual Life Outcomes. 2016;14:153","journal-title":"Turkey Health Qual Life Outcomes"},{"key":"10240_CR15","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cgh.2011.09.031","volume":"10","author":"JH Kim","year":"2012","unstructured":"Kim JH, Kwon SY, Lee YS, Lee JH, Lee YS, Lee CH. Virologic response to therapy increases health-related quality of life for patients with chronic hepatitis B. Clin Gastroenterol Hepatol. 2012;10:291\u2013296","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10240_CR16","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cgh.2018.02.037","volume":"16","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Stepanova M, Janssen HLA, Agarwal K, Nguyen MH, Gane E, et al. Effects of treatment of chronic Hepatitis B virus infection on patient-reported outcomes. Clin Gastroenterol Hepatol. 2018;16:1641\u20131649","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10240_CR17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/PPA.S127139","volume":"11","author":"X Xue","year":"2017","unstructured":"Xue X, Cai S, Ou H, Zheng C, Wu X. Health-related quality of life in patients with chronic hepatitis B during antiviral treatment and off-treatment. Patient Prefer Adherence. 2017;11:85\u201393","journal-title":"Patient Prefer Adherence"},{"key":"10240_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/14712598.2018.1451511","volume":"18","author":"X Wu","year":"2018","unstructured":"Wu X, Shi Y, Zhou J, Sun Y, Piao H, Jiang W, et al. Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study. Expert Opin Biol Ther. 2018;18:61\u201369","journal-title":"Expert Opin Biol Ther"},{"key":"10240_CR19","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jclinepi.2004.12.008","volume":"58","author":"CL Lam","year":"2005","unstructured":"Lam CL, Tse EY, Gandek B, Fong DY. The SF-36 summary scales were valid, reliable, and equivalent in a Chinese population. J Clin Epidemiol. 2005;58:815\u2013822","journal-title":"J Clin Epidemiol"},{"key":"10240_CR20","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1177\/147323000903700425","volume":"37","author":"BGH Qu","year":"2009","unstructured":"Qu BGH, Liu J, Zhang Y, Sun G. Reliability and validity testing of the SF-36 questionnaire for the evaluation of the quality of life of Chinese urban construction workers. J Int Med Res. 2009;37:1184\u20131190","journal-title":"J Int Med Res"},{"key":"10240_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11136-004-0612-6","volume":"14","author":"H Wang","year":"2005","unstructured":"Wang H, Kindig DA, Mullahy J. Variation in Chinese population health related quality of life: results from a EuroQol study in Beijing. China Qual Life Res. 2005;14:119\u2013132","journal-title":"China Qual Life Res"},{"key":"10240_CR22","volume-title":"SF-36\u00ae Physical and Mental Health Summary Scales: A User's Manual","author":"JEKM Ware","year":"1994","unstructured":"Ware JEKM, Keller SK. SF-36\u00ae Physical and Mental Health Summary Scales: A User's Manual. Boston: The Health Institute; 1994"},{"key":"10240_CR23","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.jval.2014.05.007","volume":"17","author":"GG Liu","year":"2014","unstructured":"Liu GG, Wu H, Li M, Gao C, Luo N. Chinese time trade-off values for EQ-5D health states. Value Health. 2014;17:597\u2013604","journal-title":"Value Health"},{"key":"10240_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/MCG.0000000000001179","volume":"53","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, Henry L. A comprehensive review of patient-reported outcomes in patients with chronic liver diseases. J Clin Gastroenterol. 2019;53:331\u2013341","journal-title":"J Clin Gastroenterol"},{"key":"10240_CR25","doi-asserted-by":"crossref","unstructured":"Draak THP, de Greef BTA, Faber CG, Merkies ISJ, PeriNomS study group. The minimum clinically important difference: which direction to take. Eur J Neurol. 2019;26:850\u2013855","DOI":"10.1111\/ene.13941"},{"key":"10240_CR26","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3109\/07853890109002089","volume":"33","author":"RD Hays","year":"2001","unstructured":"Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350\u2013357","journal-title":"Ann Med"},{"key":"10240_CR27","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/hep.26301","volume":"58","author":"GL Wong","year":"2013","unstructured":"Wong GL, Chan HL, Mak CW, Lee SK, Ip ZM, Lam AT, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology. 2013;58:1537\u20131547","journal-title":"Hepatology"},{"key":"10240_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/SGA.0000000000000339","volume":"41","author":"NV Fotos","year":"2018","unstructured":"Fotos NV, Elefsiniotis I, Patelarou A, Giakoumidakis K, Patelarou E, Kouros A, et al. Psychological disorders and quality of life among patients with chronic viral hepatitis: a single-center cross-sectional study with pair-matched healthy controls. Gastroenterol Nurs. 2018;41:206\u2013218","journal-title":"Gastroenterol Nurs"},{"key":"10240_CR29","first-page":"279","volume":"61","author":"AS Lok","year":"1985","unstructured":"Lok AS, van Leeuwen DJ, Thomas HC, Sherlock S. Psychosocial impact of chronic infection with hepatitis B virus on British patients. Genitourin Med. 1985;61:279\u2013282","journal-title":"Genitourin Med"},{"key":"10240_CR30","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1478-3231.2007.01558.x","volume":"27","author":"S Bondini","year":"2007","unstructured":"Bondini S, Kallman J, Dan A, Younoszai Z, Ramsey L, Nader F, et al. Health-related quality of life in patients with chronic hepatitis B. Liver Int. 2007;27:1119\u20131125","journal-title":"Liver Int"},{"key":"10240_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/COC.0b013e3181cae782","volume":"33","author":"Q Zhang","year":"2010","unstructured":"Zhang Q, Tang D, Zhao H. Immunological therapies can relieve aromatase inhibitor-related joint symptoms in breast cancer survivors. Am J Clin Oncol. 2010;33:557\u2013560","journal-title":"Am J Clin Oncol"},{"key":"10240_CR32","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3109\/08923973.2015.1069837","volume":"37","author":"Z Jia","year":"2015","unstructured":"Jia Z, Feng Z, Tian R, Wang Q, Wang L. Thymosin \u03b11 plus routine treatment inhibit inflammatory reaction and improve the quality of life in AECOPD patients. Immunopharmacol Immunotoxicol. 2015;37:388\u2013392","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10240_CR33","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/apt.15618","volume":"51","author":"DM Evon","year":"2020","unstructured":"Evon DM, Lin HS, Khalili M, Fontana RJ, Yim C, Wahed AS, et al. Patient-reported outcomes in a large North American cohort living with chronic hepatitis B virus: a cross-sectional analysis. Aliment Pharmacol Ther. 2020;51:457\u2013468","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-021-10240-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-021-10240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,8]],"date-time":"2021-12-08T02:05:11Z","timestamp":1638929111000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-021-10240-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,29]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["10240"],"URL":"https:\/\/doi.org\/10.1007\/s12072-021-10240-4","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,29]]},"assertion":[{"value":"2 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jidong Jia has provided consulting to BMS, Gilead, GSK, J&J and Roche, has received research support from Gilead, and is currently principle investigator of Brii Biosciences and Huahui Health Ltd. Hong You has provided consulting to and participated in clinical trials of J&J, Aligos, Brii Biosciences, Huahui Health Ltd, and Suzhou Ribo Life Science Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trial and long-term follow-up study were conducted following the ethical principles enshrined in the Declaration of Helsinki and complied with Good Clinical Practice guidelines and the applicable local regulatory requirements. Each patient provided written informed consent before participation. The studies were registered with the ClinicalTrials.gov identifier NCT01943617 and NCT02849132.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}